NCT04336241 2026-02-27Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsReplimune Inc.Phase 1 Active not recruiting36 enrolled
NCT04180371 2025-11-17Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx LimitedPhase 1/2 Active not recruiting288 enrolled
NCT04278144 2025-09-15A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsBolt Biotherapeutics, Inc.Phase 1/2 Terminated175 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled